Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Eiger BioPharmaceuticals, Inc. [EIGR]
Reports for Purchase
Showing records 21 - 40 ( 112 total )
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials - Pipeline Update; Next Zokinvy-/Progeria Nov 20 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1; Zokinvy Progeria: Priority Review - PDUFA Date Set to November 20, 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MAA Validated; We Estimate FDA Acceptance for Review in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Delayed Completion of D-LIVR Patient Enrollment Due to COVID-19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submitted for Lonafarnib/Progeria, We Estimate Potential Launch in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FY19; Progeria NDA Submission end of March; End-of- Treatment LIFT Data at EASL
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lonafarnib/Progeria NDA Submission in Q1; Avexitide/PBH Ph3 Guidance from FDA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3; Strong Interest in LIFT Data at AASLD; Lonafarnib Progeria NDA by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim End-of-Treatment Results for Phase 2 LIFT in HDV at AASLD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Lambda-lonafarnib/HDV End-of-treatment Phase 2 Data at AASLD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Breakthrough Therapy Designation for Avexitide in PBH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials and Regulatory Guidance Upcoming for Avexitide
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Financing Extends Runway to Cover Clinical, Regulatory and Commercial Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
EASL: Positive End-of-Study Results for Lambda Phase 2 LIMT Study in HDV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.